New hope for teens with fragile x: drug trial targets learning and behavior
NCT ID NCT05163808
Summary
This study tested an investigational drug, BPN14770, to see if it could improve thinking skills, language, and daily functioning in male adolescents with Fragile X Syndrome. It involved 163 boys aged 9 to 18 and compared the drug's effects to a placebo over 13 weeks. The main goal was to measure changes in cognitive and behavioral scores reported by caregivers and clinicians.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRAGILE X SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amnova Clinical Research
Irvine, California, 92604, United States
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Cincinatti Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Clinic for Special Children
Strasburg, Pennsylvania, 17579, United States
-
Emory University School of Medicine
Atlanta, Georgia, 30322, United States
-
Greenwood Genetic Center
Greenville, South Carolina, 29605, United States
-
Icahn School of Medicine at Mount Sinai Hospital
New York, New York, 10029, United States
-
Kennedy Krieger Institute
Baltimore, Maryland, 21205, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
Suburban Research Associates
Media, Pennsylvania, 19063, United States
-
Thompson Autism & Neurodevelopment Center - CHOC
Orange, California, 92868, United States
-
U Mass
Worcester, Massachusetts, 01655, United States
-
UC Davis
Sacramento, California, 95817, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Utah and Primary Childrens Hospital
Salt Lake City, Utah, 84113, United States
Conditions
Explore the condition pages connected to this study.